Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 16/20 | 0.83 |
| ▸ | FDPS | P14324 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14199557 | 0.91 | GGPS1 (0.74) | GGPS1FDPSKMT2AHDAC8 | |
| SCHEMBL12060534 | 0.80 | GGPS1 (0.56) | GGPS1FDPSHDAC8 | |
| SCHEMBL12060602 | 0.80 | GGPS1 (0.83) | GGPS1FDPSKMT2A | |
| SCHEMBL12060627 | 0.80 | GGPS1 (0.56) | GGPS1FDPSCA12MMP2CA14 | |
| SCHEMBL12060622 | 0.80 | GGPS1 (0.56) | GGPS1FDPSCA12MMP2CA14 | |
| SCHEMBL12060601 | 0.79 | GGPS1 (0.83) | GGPS1FDPSCA12MMP2CA14 | |
| SCHEMBL12060621 | 0.78 | GGPS1 (0.54) | GGPS1FDPS | |
| SCHEMBL14227952 | 0.78 | GGPS1 (0.57) | GGPS1FDPSKMT2A | |
| SCHEMBL12060612 | 0.78 | GGPS1 (0.61) | GGPS1FDPS | |
| SCHEMBL12060604 | 0.76 | GGPS1 (0.58) | GGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071573-B2 | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS (US) | 2011-12-06 | — | — | US | disclosed |
| US-8012949-B2 | Pyridinium-1-yl, quinolinium-1-yl, and related compounds; parasitic infections, for example against trypanosomes; inhibiting the enzyme farnesyl diphosphate synthase | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1802641-B1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | UNIV ILLINOIS (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20100316676-A1 | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-12-16 | — | — | US | disclosed |
| US-7745422-B2 | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080318906-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008128056-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS WITH ENHANCED POTENCY FOR MULTIPLE TARGETS INCLUDING FPPS, GGPPS, AND DPPS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255070-A1 | Bisphosphonate Compounds and Methods with Enhanced Potency for Multiple Targets including FPPS, GGPPS, AND DPPS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316676-A1 | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases | FDPS, GGPS1, MVD | GGPS1 2/4885FDPS 1/4885KMT2A 4693/4885 |
| US-20080255070-A1 | Bisphosphonate Compounds and Methods with Enhanced Potency for Multiple Targets including FPPS, GGPPS, AND DPPS | GGPS1, FDPS, FNTA | GGPS1 1/4885FDPS 2/4885KMT2A 3049/4885 |
| US-20080318906-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | FDPS, GGPS1, MVD | GGPS1 2/4885FDPS 1/4885KMT2A 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.